David Roman
Stock Analyst at Goldman Sachs
(2.08)
# 3,133
Out of 5,182 analysts
80
Total ratings
41.3%
Success rate
-3.34%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $87 → $84 | $62.07 | +35.33% | 3 | Apr 23, 2026 | |
| BDX Becton, Dickinson and Company | Reinstates: Neutral | $167 | $152.14 | +9.77% | 2 | Apr 10, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $28 → $25 | $20.36 | +22.79% | 3 | Apr 9, 2026 | |
| SYK Stryker | Maintains: Neutral | $403 → $357 | $327.51 | +9.00% | 3 | Apr 9, 2026 | |
| OMDA Omada Health | Maintains: Buy | $26 → $23 | $14.33 | +60.50% | 2 | Apr 9, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Neutral | $22 → $17 | $22.45 | -24.28% | 4 | Apr 9, 2026 | |
| IRTC iRhythm Holdings | Maintains: Neutral | $184 → $147 | $122.35 | +20.15% | 5 | Apr 9, 2026 | |
| ISRG Intuitive Surgical | Maintains: Buy | $714 → $609 | $482.22 | +26.29% | 2 | Apr 9, 2026 | |
| PODD Insulet | Maintains: Buy | $326 → $277 | $189.56 | +46.13% | 3 | Apr 9, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $97 → $81 | $68.83 | +17.68% | 4 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $28 | $24.01 | +16.62% | 6 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $10.21 | +66.50% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $20 | $11.17 | +79.05% | 4 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $121 | $91.13 | +32.78% | 3 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $17 | $18.16 | -6.39% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $95 | $84.15 | +12.89% | 5 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $49 | $44.76 | +9.47% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $89 | $82.45 | +7.94% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $64 → $71 | $64.42 | +10.21% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $81 → $111 | $83.32 | +33.22% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $15.82 | +1.14% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $103 | $121.48 | -15.21% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $12.97 | +54.20% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $104 | $91.26 | +13.96% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $5.75 | +73.91% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $63 → $71 | $68.52 | +3.62% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $55 | $64.20 | -14.33% | 2 | Mar 3, 2025 |
Boston Scientific
Apr 23, 2026
Maintains: Buy
Price Target: $87 → $84
Current: $62.07
Upside: +35.33%
Becton, Dickinson and Company
Apr 10, 2026
Reinstates: Neutral
Price Target: $167
Current: $152.14
Upside: +9.77%
Tandem Diabetes Care
Apr 9, 2026
Maintains: Neutral
Price Target: $28 → $25
Current: $20.36
Upside: +22.79%
Stryker
Apr 9, 2026
Maintains: Neutral
Price Target: $403 → $357
Current: $327.51
Upside: +9.00%
Omada Health
Apr 9, 2026
Maintains: Buy
Price Target: $26 → $23
Current: $14.33
Upside: +60.50%
Kestra Medical Technologies
Apr 9, 2026
Maintains: Neutral
Price Target: $22 → $17
Current: $22.45
Upside: -24.28%
iRhythm Holdings
Apr 9, 2026
Maintains: Neutral
Price Target: $184 → $147
Current: $122.35
Upside: +20.15%
Intuitive Surgical
Apr 9, 2026
Maintains: Buy
Price Target: $714 → $609
Current: $482.22
Upside: +26.29%
Insulet
Apr 9, 2026
Maintains: Buy
Price Target: $326 → $277
Current: $189.56
Upside: +46.13%
GE HealthCare Technologies
Apr 9, 2026
Maintains: Buy
Price Target: $97 → $81
Current: $68.83
Upside: +17.68%
Apr 9, 2026
Maintains: Neutral
Price Target: $34 → $28
Current: $24.01
Upside: +16.62%
Apr 9, 2026
Maintains: Buy
Price Target: $19 → $17
Current: $10.21
Upside: +66.50%
Apr 9, 2026
Maintains: Buy
Price Target: $23 → $20
Current: $11.17
Upside: +79.05%
Apr 9, 2026
Maintains: Buy
Price Target: $140 → $121
Current: $91.13
Upside: +32.78%
Feb 17, 2026
Maintains: Neutral
Price Target: $21 → $17
Current: $18.16
Upside: -6.39%
Feb 11, 2026
Maintains: Buy
Price Target: $108 → $95
Current: $84.15
Upside: +12.89%
Jan 12, 2026
Initiates: Buy
Price Target: $49
Current: $44.76
Upside: +9.47%
Jan 9, 2026
Downgrades: Sell
Price Target: $89
Current: $82.45
Upside: +7.94%
Dec 8, 2025
Maintains: Sell
Price Target: $64 → $71
Current: $64.42
Upside: +10.21%
Nov 19, 2025
Upgrades: Neutral
Price Target: $81 → $111
Current: $83.32
Upside: +33.22%
Oct 1, 2025
Initiates: Neutral
Price Target: $16
Current: $15.82
Upside: +1.14%
Oct 1, 2025
Initiates: Buy
Price Target: $103
Current: $121.48
Upside: -15.21%
Aug 25, 2025
Initiates: Buy
Price Target: $20
Current: $12.97
Upside: +54.20%
May 6, 2025
Maintains: Neutral
Price Target: $120 → $104
Current: $91.26
Upside: +13.96%
May 1, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $5.75
Upside: +73.91%
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $68.52
Upside: +3.62%
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $64.20
Upside: -14.33%